Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc R Barnard

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Blood|February 2, 2012
In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activationBethan Psaila, James B Bussel, Matthew D Linden, et al.
Blood|February 12, 2005
Platelet activation in cystic fibrosisBrian P O'Sullivan, Matthew D Linden, Andrew L Frelinger, et al.
Plos One|September 21, 2011
The human endogenous circadian system causes greatest platelet activation during the biological morning independent of behaviorsFrank A J L Scheer, Alan D Michelson, Andrew L Frelinger, et al.
Thrombosis and Haemostasis|June 29, 2007
The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: Influence of other blood cells, calcium, and aspirinAndrew L Frelinger, Joseph A Jakubowski, Youfu Li, et al.
Journal of Vascular Surgery|February 4, 2003
The cleaved peptide of PAR1 is a more potent stimulant of platelet-endothelial cell adhesion than is thrombinR Brannon Claytor, Alan D Michelson, Jian-Ming Li, et al.
Journal of the American College of Cardiology|January 22, 2013
Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet functionAndrew L Frelinger, Deepak L Bhatt, Ronald D Lee, et al.
American Heart Journal|February 22, 2003
Quantification of abciximab-induced platelet inhibition is assay dependent: a comparative study in patients undergoing percutaneous coronary interventionMark I Furman, Dean J Kereiakes, Lori A Krueger, et al.
Blood|July 31, 2015
Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syndrome/X-linked thrombocytopeniaAnja J Gerrits, Emily A Leven, Andrew L Frelinger, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Blood|February 2, 2012
In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activationBethan Psaila, James B Bussel, Matthew D Linden, et al.
Blood|February 12, 2005
Platelet activation in cystic fibrosisBrian P O'Sullivan, Matthew D Linden, Andrew L Frelinger, et al.
Plos One|September 21, 2011
The human endogenous circadian system causes greatest platelet activation during the biological morning independent of behaviorsFrank A J L Scheer, Alan D Michelson, Andrew L Frelinger, et al.
Thrombosis and Haemostasis|June 29, 2007
The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: Influence of other blood cells, calcium, and aspirinAndrew L Frelinger, Joseph A Jakubowski, Youfu Li, et al.
Journal of Vascular Surgery|February 4, 2003
The cleaved peptide of PAR1 is a more potent stimulant of platelet-endothelial cell adhesion than is thrombinR Brannon Claytor, Alan D Michelson, Jian-Ming Li, et al.
Journal of the American College of Cardiology|January 22, 2013
Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet functionAndrew L Frelinger, Deepak L Bhatt, Ronald D Lee, et al.
American Heart Journal|February 22, 2003
Quantification of abciximab-induced platelet inhibition is assay dependent: a comparative study in patients undergoing percutaneous coronary interventionMark I Furman, Dean J Kereiakes, Lori A Krueger, et al.
Blood|July 31, 2015
Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syndrome/X-linked thrombocytopeniaAnja J Gerrits, Emily A Leven, Andrew L Frelinger, et al.
Pageof 3